An interventional study of Talent Abdominal Stent Graft in Aortic Aneurysm, Abdominal, sponsored by Medtronic Cardiovascular. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.
Sponsored by Medtronic Cardiovascular · Not applicable, Interventional, and Treatment
The purpose of this study is to examine, through the endpoints established in this protocol, the long-term safety and effectiveness of the Talent Abdominal Stent Graft System, in a post-approval environment.
The Talent Abdominal Stent Graft System is a next-generation modular system for endovascular repair of Abdominal Aortic Aneurysm (AAA). The system was designed with the following enhancements: a suprarenal wire frame to provide migration resistance, and improved flexibility designed to treat difficult anatomies.
Medtronic Vascular submitted a Pre-Market Application (PMA) to the Food and Drug Administration (FDA) on October 17, 2007, and received market approval for the Talent Abdominal Stent Graft System on April 15th, 2008. As a condition of approval, the FDA has requested a post-approval study. Medtronic has therefore designed a post-approval study, in collaboration with FDA, to document the performance of the Talent Abdominal Stent Graft System under market conditions.
960 studies on the registry are indexed under Aneurysm; 174 are open to participants now.
This study's enrollment of 94 is above the median of 72 across 461 interventional studies indexed under Aneurysm.
Browse Aneurysm studies →Medtronic Cardiovascular is the lead sponsor of 66 studies on the registry; 7 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients diagnosed with an abdominal aortic or aorto-iliac aneurysm that are considered candidates for endovascular repair, per the FDA approved IFU.
Device: Talent Abdominal Stent Graft
The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
Freedom From Aneurysm-related Mortality (ARM)
ARM is defined as death from rupture of the abdominal aortic aneurysm or from any procedure intended to treat the Abdominal Aortic Aneurysm (AAA). If a death occurred within 30 days of any procedure intended to treat the AAA, then it is presumed to be aneurysm related unless there is evidence to the contrary. Deaths occurring after 30 days of any procedure intended to treat the AAA that are procedure-related should also be aneurysm related. All deaths were adjudicated by a Clinical Events Committee (CEC) to determine aneurysm, device and/or procedure relatedness.
Time frame: 5 year Kaplan Meier (KM)
| Milestone | Talent Abdominal Stent Graft |
|---|---|
| Started | 260 |
| Completed | 133 |
| Not completed | 127 |
ARM is defined as death from rupture of the abdominal aortic aneurysm or from any procedure intended to treat the Abdominal Aortic Aneurysm (AAA). If a death occurred within 30 days of any procedure intended to treat the AAA, then it is presumed to be aneurysm related unless there is evidence to the contrary. Deaths occurring after 30 days of any procedure intended to treat the AAA that are procedure-related should also be aneurysm related. All deaths were adjudicated by a Clinical Events Committee (CEC) to determine aneurysm, device and/or procedure relatedness.
| Proportion of participants | Treatment |
|---|---|
| Freedom From Aneurysm-related Mortality (ARM) | .97 (.946 to .994) |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1. Vitality | — | 31/94 (33%) | 5/94 (5.3%) |
| 2. ELPS | — | 99/166 (59.6%) | 112/166 (67.5%) |
| Event | 1. Vitality | 2. ELPS |
|---|---|---|
| Stent-Graft EndoleakGeneral disorders | 2/94 | 24/166 |
| HaemorrhageVascular disorders | 0/94 | 10/166 |
| Arterial Occlusive DiseaseVascular disorders | 5/94 | 0/166 |
| Cardiac Failure CongestiveCardiac disorders | 4/94 | 4/166 |
| ArrhythmiaCardiac disorders | 3/94 | 6/166 |
| AnaemiaBlood and lymphatic system disorders | 3/94 | 3/166 |
| Myocardial InfarctionCardiac disorders | 3/94 | 3/166 |
| Renal FailureRenal and urinary disorders | 3/94 | 4/166 |
| SeromaInjury, poisoning and procedural complications | 0/94 | 5/166 |
| Ill-Defined DisorderGeneral disorders | 0/94 | 4/166 |
| Event | 1. Vitality | 2. ELPS |
|---|---|---|
| Stent-Graft EndoleakGeneral disorders | 5/94 | 67/166 |
| AnaemiaBlood and lymphatic system disorders | 0/94 | 21/166 |
| PyrexiaGeneral disorders | 0/94 | 21/166 |
| Ill-Defined DisorderGeneral disorders | 0/94 | 20/166 |
| HaemorrhageVascular disorders | 0/94 | 20/166 |
| SeromaInjury, poisoning and procedural complications | 0/94 | 15/166 |
| Back PainMusculoskeletal and connective tissue disorders | 0/94 | 9/166 |
| Renal FailureRenal and urinary disorders | 0/94 | 9/166 |
| Age, Continuous(years) | Treatment |
|---|---|
| Mean | 73.7 ± 7.9 |
| Sex: Female, Male(Participants) | Treatment |
|---|---|
| Female | 33 |
| Male | 227 |
| Ethnicity (NIH/OMB)(Participants) | Treatment |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 254 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Treatment |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 241 |
| More than one race | 5 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Treatment |
|---|---|
| United States | 260 |
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medtronic Cardiovascular